Drug maker TaiGen Biotechnology Co (太景生技) said yesterday that a drug it developed to treat pneumonia and skin infections was approved on Dec. 20 for the US Food and Drug Administration (FDA) fast track development system, which could result in it receiving a drug permit at an earlier date.
“Being on the fast track will allow us to meet with officials from the US Food and Drug Administration more frequently, allowing us to provide them with necessary data and meet their requirements within a shorter period of time,” TaiGen vice president Peter Tsao (邵榮凱) said by telephone yesterday. Tsao did not give an estimate for when the drug will be approved.
Tsao said the reason the medication was put on the fast track was because the drug — nemonoxacin — targets an unmet medical need in the US.
Meanwhile, the US government also agreed to grant TaiGen and its partners exclusive rights to sell the drug for 10 years after it goes on sale in the US market, the company said.
The company already has a patent for nemonoxacin until 2029, and the rights granted by the US government will provide the firm with extra protection as the patent is likely to be challenged by other companies, Tsao said.
Having passed Phase II clinical trials in the US, the TaiGen drug is ready Phase III trials and the company is looking for firms to purchase the drug, Tsao said. The fast track status and exclusive rights will make the drug more attractive for potential partners, he added.
From January through last month, TaiGen registered revenues of NT$63.35 million, up 84.51 percent from NT$34.33 million a year ago, according to the company’s filing to the Taiwan Stock Exchange.
However, the company still posted losses of NT$271.86 million in the January to September period as the result of its high research and development costs, the filing showed. The figure was down 48.39 percent from losses of NT$526.73 million last year.
‘BIG LOSS’: This year might see the last generation of Huawei’s Kirin chips, as their production would stop next month because they are made using US technology Chinese tech giant Huawei Technologies Co (華為) is running out of processor chips to make smartphones due to US sanctions and would be forced to stop production of its own most advanced chips, a company executive has said, in a sign of growing damage to Huawei’s business from US pressure. Huawei, one of the biggest producers of smartphones and network equipment, is at the center of US-Chinese tension over technology and security. Washington last year cut off Huawei’s access to US components and technology, and those penalties were tightened in May, when the White House barred vendors worldwide from using US
CORPORATE SCANDAL: Cathay Life has invested NT$13.3 billion in Bank Mayapada since 2015, but the latest loss of NT$8.8 billion has completely written off its investment Cathay Life Insurance Co (國泰人壽) yesterday said it would recognize an investment loss of NT$8.8 billion (US$298.1 million) in Indonesia’s Bank Mayapada Internasional Tbk PT due to concerns about the lender’s operations amid a corporate scandal. The company said it would revise its earnings result for June, from a net profit of NT$6.52 billion to a net loss of NT$520 million, its first monthly loss over the past 17 months. After booking an investment loss of NT$5.2 billion in Bank Mayapada earlier this year, Cathay Life has so far recognized total investment losses of NT$14 billion in the lender, executive vice president
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reported that revenue last month expanded 25 percent annually, but fell 12.8 percent month-on-month to NT$105.96 billion (US$3.59 billion). In the first seven months of this year, the chipmaker’s revenue surged 33.6 percent to NT$727.26 billion, compared with NT$544.46 billion a year earlier. TSMC has said it aims to grow its revenue by more than 20 percent this year. The company has since May 15 stopped taking new orders from Huawei Technologies Co (華為), its second-biggest customer after Apple Inc, due to the US’ restrictions on exports containing US technologies. TSMC has no plans to
The US stock market has been on a tear, yet the country’s economy is in the dumps. So why do so many people believe — undoubtedly incorrectly — that the stock market has decoupled from reality? The economy many people experience, while bleak, is local, personal and, for the most part, either not publicly traded or plays only a small part in the stock market’s moves. To explain why these personal experiences have so little effect on equity markets, we must look more closely at the market role of the weakest industry sectors. The surprising conclusion: The most visible and economically vulnerable